Case of fulminant type 1 diabetes induced by the anti‐programmed death‐ligand 1 antibody, avelumab

With the expansive use of immune checkpoint inhibitors, the frequency of immune‐related adverse events, including autoimmune type 1 diabetes, has been exponentially increased. The anti‐programmed death‐ligand 1 antibody, avelumab, has recently been approved for metastatic Merkel cell carcinoma thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Shibayama, Yui, Kameda, Hiraku, Ota, Shoichiro, Tsuchida, Kazuhisa, Cho, Kyu Yong, Nakamura, Akinobu, Miyoshi, Hideaki, Atsumi, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717815/
https://www.ncbi.nlm.nih.gov/pubmed/30738003
http://dx.doi.org/10.1111/jdi.13022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717815/
https://www.ncbi.nlm.nih.gov/pubmed/30738003
http://dx.doi.org/10.1111/jdi.13022

Ejemplares similares